@article{CCO17298,
author = {Stephen J. Luen and Sherene Loi},
title = {Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer},
journal = {Chinese Clinical Oncology},
volume = {7},
number = {1},
year = {2017},
keywords = {},
abstract = {Giant strides in the development of HER2-targeted agents have drastically improved outcomes for patients diagnosed with HER2-amplified breast cancer. Despite this, most patients who develop a recurrence inevitably die from their disease. More recently, anti-tumor adaptive T cell immune responses have been shown to be able to significantly influence both prognosis as well as response and benefit to therapies in early stage disease (1-3). Analyses assessing the role of tumor-infiltrating lymphocytes (TIL) in the setting of advanced HER2-positive breast cancer are only just beginning to emerge.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/17298}
}